gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Protein tyrosine phosphatase, receptor type, F

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and two tandem intracytoplasmic catalytic domains, and thus represents a receptor-type PTP. The extracellular region contains three Ig-like domains, and nine non-Ig like domains similar to that of neural-cell adhesion molecule. This PTP was shown to function in the regulation of epithelial cell-cell contacts at adherents junctions, as well as in the control of beta-catenin signaling. An increased expression level of this protein was found in the insulin-responsive tissue of obese, insulin-resistant individuals, and may contribute to the pathogenesis of insulin resistance. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: HAD, CAN, Insulin, somatostatin, ACID
Papers on LAR
Pasireotide for malignant insulinoma.
Shimon et al., In Hormones (athens), Feb 2016
The glycemic control achieved with pasireotide LAR was better compared with lanreotide and everolimus.
Quantitative analysis of pasireotide (SOM230), a cyclic peptide, in monkey plasma using liquid chromatography in combination with tandem mass spectrometry.
Tse et al., United States. In J Chromatogr B Analyt Technol Biomed Life Sci, Feb 2016
The validated method was successfully implemented to support a toxicity study in monkeys administered with 5 and 30mg of SOM230 in a single intramuscular injection of a long acting release (LAR) formulation.
Reaching the brain: Advances in optic nerve regeneration.
Goldberg et al., In Exp Neurol, Jan 2016
More recently, some degree of regeneration has been achieved through the optic nerve itself by factors associated with intraocular inflammation (oncomodulin) or by altering levels of particular transcription factors (Klf-4, -9, c-myc), cell-intrinsic suppressors of axon growth (PTEN, SOCS3), receptors to cell-extrinsic inhibitors of axon growth (Nogo receptor, LAR, PTP-σ) or the intracellular signaling pathway activated by these receptors (RhoA).
Design, synthesis and in vitro activity of phidianidine B derivatives as novel PTP1B inhibitors with specific selectivity.
Guo et al., Shanghai, China. In Bioorg Med Chem Lett, Jan 2016
Their inhibitory effects on PTP1B and other PTPs (TCPTP, SHP1, SHP2 and LAR) were evaluated.
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Pivonello et al., Napoli, Italy. In Pituitary, Sep 2015
Various studies of first-line treatment with octreotide LAR have shown significant TVR in ≥73 % of patients.
METALLOPROTEINS. A tethered niacin-derived pincer complex with a nickel-carbon bond in lactate racemase.
Hausinger et al., East Lansing, United States. In Science, Aug 2015
Lactate racemase (Lar) requires nickel, but the nickel-binding site and the role of three accessory proteins required for its activation remain enigmatic.
Targeted Therapies in Triple-Negative Breast Cancer.
Schneeweiss et al., Heidelberg, Germany. In Breast Care (basel), Jul 2015
Currently, bevacizumab, a monoclonal anti-vascular endothelial growth factor (VEGF)-A antibody, is the only targeted agent with an approval for the therapy of metastatic breast cancer, but does not provide a specific benefit in the TNBC subtype.
Pasireotide in Acromegaly: A Review.
McKeage, Auckland, New Zealand. In Drugs, Jun 2015
Pasireotide (Signifor(®), Signifor(®) LAR) is a somatostatin analogue recently approved for the treatment of acromegaly.
Local allergic rhinitis: mechanisms, diagnosis and relevance for occupational rhinitis.
Campo et al., Málaga, Spain. In Curr Opin Allergy Clin Immunol, Apr 2015
PURPOSE OF REVIEW: Local allergic rhinitis (LAR) is a new form of allergic rhinitis that has caused a growing interest.
Modulation of the proteoglycan receptor PTPσ promotes recovery after spinal cord injury.
Silver et al., Cleveland, United States. In Nature, Mar 2015
Protein tyrosine phosphatase σ (PTPσ), along with its sister phosphatase leukocyte common antigen-related (LAR) and the nogo receptors 1 and 3 (NgR), have recently been identified as receptors for the inhibitory glycosylated side chains of CSPGs.
[Recent advances in allergic rhinitis].
Xu et al., In Lin Chuang Er Bi Yan Hou Ke Za Zhi, Feb 2015
Current studies have demonstrated local allergic rhinitis (LAR) that patients with both sug- gestive symptoms of AR and a negative diagnostic test for atopy may have local allergic inflammation is a prevalent entity in patients evaluated with rhinitis, but further research remains needed.
Transcriptomic analysis of Camellia ptilophylla and identification of genes associated with flavonoid and caffeine biosynthesis.
Hang et al., Nanjing, China. In Genet Mol Res, 2014
In catechin biosynthesis, leucoanthocyanidin reductase (LAR) catalyzes the transition of leucoanthocyanidin to trans-catechins, while anthocyanidin synthase (ANS) and anthocyanidin reductase (ANR) catalyze cis-catechin production.
The receptor tyrosine phosphatase Lar regulates adhesion between Drosophila male germline stem cells and the niche.
Fuller et al., Stanford, United States. In Development, 2012
the Lar receptor tyrosine phosphatase appears to polarize and retain GSCs through maintenance of localized E-cadherin-based adherens junctions
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
RADIANT-2 Study Group et al., Berlin, Germany. In Lancet, 2012
We aimed to assess the combination of everolimus plus octreotide long-acting repeatable (LAR) in patients with low-grade or intermediate-grade neuroendocrine tumours (carcinoid).
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pollak et al., Toronto, Canada. In J Clin Oncol, 2011
PURPOSE: Somatostatin analogs act directly on breast cancer cells and indirectly on insulin and insulin-like growth factor 1 (IGF-1) levels.
Leukocyte common antigen-related phosphatase is a functional receptor for chondroitin sulfate proteoglycan axon growth inhibitors.
Li et al., Dallas, United States. In J Neurosci, 2011
Deletion of LAR in knock-out mice or blockade of LAR with sequence-selective peptides significantly overcomes neurite growth restrictions of chondroitin sulfate proteoglycan in neuronal cultures.
The LAR protein tyrosine phosphatase enables PDGF β-receptor activation through attenuation of the c-Abl kinase activity.
Hellberg et al., Uppsala, Sweden. In Cell Signal, 2011
LAR reduces the basal c-Abl activity thereby allowing for platelet derived growth factor beta receptor kinase activation
The immunoglobulin-like domains 1 and 2 of the protein tyrosine phosphatase LAR adopt an unusual horseshoe-like conformation.
Bouyain et al., Kansas City, United States. In J Mol Biol, 2011
the crystal structures of the first and second immunoglobulin-like domains of the Drosophila type IIa receptor Dlar and its mouse homolog LAR were reported.
The cytoplasmic adaptor protein Caskin mediates Lar signal transduction during Drosophila motor axon guidance.
Broihier et al., Cleveland, United States. In J Neurosci, 2011
Drosophila caskin (ckn) is necessary for embryonic motor axon pathfinding and interacts genetically and physically with the leukocyte common antigen-related
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Wiedenmann et al., Houston, United States. In J Clin Oncol, 2010
Coadministration of octreotide LAR and everolimus did not impact exposure to either drug.
share on facebooktweetadd +1mail to friends